The trade wars between the United States with China, Mexico, Canada and other former strategic trading partners has slowed down the bullish stock market. Tariffs and other retaliatory economic measures have increased the cost of goods and caused investors to be more conservative with their stock trading due to a growing concern of a recession.
According to an article by the Wall Street Journal (https://www.wsj.com/articles/how-higher-
tariffs-affect-different-industries-11557513451), the U.S. tariff hike on certain Chinese imports
largely spares finished medical devices , though they include some categories such as electrical
nerve stimulation machines and medical-imaging components.
Medical-technology manufacturers and pharmaceutical companies and their allies in Congress
have lobbied to exclude many products from the Trump administration’s tariff actions.
In a prior round of tariff actions last year, industry lobbyists persuaded the administration to
reduce the total value of medical technologies subject to new tariffs to less than $1 billion, from
initial proposals of about $3 billion.
Industry trade group AdvaMed, whose members include Johnson & Johnson and Medtronic Plc, has opposed the tariffs. “We remain hopeful for a successful conclusion of the negotiations, which are delicate and with broad-reaching implications that our industry is watching closely on behalf of the patients we serve,” Ralph Ives, AdvaMed executive vice president of global strategy and analysis, said in a statement.
Industrial stocks are considered particularly vulnerable to tariffs , because many industrial
products are subject to the tariffs. Car and auto-parts companies are also vulnerable , as their
costs are likely to rise considerably.
The Industrial Select Sector SPDR ETF (ticker: XLI) was down 1.1% in midday trading.
Companies feeling the pressure included farm equipment maker Deere (DE), down 4.1%, and
auto-parts company BorgWarner (BWA), which fell 2.1%.
Furniture companies have also been hit by the tariffs, and could suffer more. Hooker
Furniture stock (HOFT) was down 2.4%.
Value Investors are taking notice of this trend, which bodes well for fundamentally strong
companies who are undervalued in the current OTC landscape. One highly undervalued OTC
Markets company to be on the look out for is Innovus Pharmaceuticals, Inc. (OTCQB:
INNV). INNV can best be characterized as a leader in developing and direct to consumers
marketing of new OTC and branded Abbreviated New Drug Application (“ANDA”) products while actively pursuing opportunities where existing prescription drugs have recently, or are expected to, switch from prescription (or Rx) to OTC.
Innovus sells over 35 impressive products, some of which are available in such big box stores as Kroger and Fred Meyer in the United States. Innovus is also available in print, mail and in other online ecommerce platforms such as on Amazon® , which can be viewed at https://innovuspharma.com/.
A few of INNV notable drugs either currently marketed or are expected to be marketed this year
target large markets where there is a need for a new national brand entrant and include Rogaine ®™ competitor Regoxidine™, a topical foam containing 5% minoxidil that is approved by the FDA as a hair regrowth treatment and is used to grow hair on the top of the ®scalp; OmepraCare™,the competitor of Prilosec®. The Company has a strong track record of success with products like FlutiCare® which in under two years ranked second after Flonase in the largest online sales channels like Amazon ® . The Company also entered the rapidly growing CBD market with their hemp derived Cannabidiol product MZS Sleeping Aid™. Innovus appears poised for continued growth, especially with their emerging revenues from targeted markets in Canada, United States, Asia and the European Union.
This article will be highlighting companies that deliver safe, innovative and effective over-the-
counter medicine and consumer care products to improve men’s and women's health worldwide.
The companies we’re highlighting today include: Innovus Pharmaceuticals, Inc. (INNV), Pfizer Inc. (PFE), Johnson & Johnson (JNJ), Youngevity International, Inc. (YGYI), and MERCK Kommanditgesellschaft auf Aktien (MKGAF).
Innovus Pharmaceuticals, Inc. (INNV) (Market Cap: $3.936M, Share Price: $1.50),
Innovus Pharma is an emerging over the counter (“OTC”) consumer goods and specialty
pharmaceutical company engaged in the commercialization, licensing and development of safe
and effective non-prescription medicine and consumer care products to improve men’s and
women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and
uniquely presented and packaged health solutions through its (a) OTC medicines and consumer
and health products, which we market directly, (b) commercial partners to primary care
physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our
on-line channels, retailers and wholesalers.
Pfizer Inc. (PFE) (Market Cap: $237.742B, Share Price: $42.76), Pfizer Inc.
discovers, develops, manufactures, and sells healthcare products worldwide. It has many
divisions including a large OTC division. Although the largest revenue generating segment for
the Company is from its Rx division, its OTC or consumer healthcare business generated over
$3.5B in revenues for 2017 according to the Company SEC filings. Pfizer’s consumer healthcare products include dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names.
Johnson & Johnson (JNJ) (Market Cap: $371.946B, Share Price: $140.09), Johnson &
Johnson together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer,
Pharmaceutical, and Medical Devices. The Consumer segment generated $1B in revenues in
2017 from baby care products under the JOHNSON brand; oral care products under the
LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO,
JOHNSONS Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides womens health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and O.B. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand.
Youngevity International, Inc. (YGYI) (Market Cap: $154.853M, Share Price: $5.36), Youngevity is a leading omni-direct lifestyle company offering a hybrid of the direct
selling business model, that also offers e-commerce and the power of social selling. Assembling
a virtual Main Street of products and services under one corporate entity YGYI offers products
from the eight top-selling retail categories: health/nutrition, home/family, food/beverage
(including coffee), spa/beauty, fashion, essential oils, photo, as well as innovative services.
MERCK KGaA (MKGAF) (Market Cap: $39.567B, Share Price: $102.05), MERCK KGaA, or the Merck Group, operates in the healthcare, life science, and performance materials sectors worldwide. Merck KgaA consumer healthcare division is another example of a steady profitable revenue generating business as it delivered to the Company €3.4B in revenues when it sold its consumer care business to EMD Serono in December 2018.
The trade wars will not last forever and neither will the bargains some stocks are trading at.
Value Investors are monitoring these five stocks above closely, but they surely won’t be the only
new shareholders these companies receive. Multiple other investor types are taking notice too.
These companies have tremendous upside and are undervalued. We encourage all investors to do some due diligence on these five stocks.
As concerned as investors may be about the regulatory issues, health care stocks have
traditionally offered investors growth opportunities and acted as safe havens in troubled times.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with Innovus Pharmaceuticals, Inc. (INNV) signed 05/20/2019. The agreement calls for $20,000 in cash and 10,000 restricted 144 shares per month. All payments were made directly by Innovus Pharmaceuticals, Inc. to Regal Consulting, LLC to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. INNV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Full Legal Disclaimer Click Here.
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Country: United States